ABSTRACT: A 10-wk-old infant girl with severe hypertrophy of the septal and atrial walls by cardiac ultrasound, developed progressive ventricular wall thickening and died of aspiration pneumonia at 5 mo of age. Postmortem examination revealed ventricular hypertrophy and massive atrial wall thickening due to glycogen accumulation. A skeletal muscle biopsy showed increased free glycogen and decreased activity of phosphorylase b kinase (PHK). The report of a pathogenic mutation (R531Q) in the gene (PRKAG2) encoding the ␥2 subunit of AMP-activated protein kinase (AMPK) in three infants with congenital hypertrophic cardiomyopathy, glycogen storage, and "pseudo PHK deficiency" prompted us to screen this gene in our patient. We found a novel (R384T) heterozygous mutation in PRKAG2, affecting an arginine residue in the N-terminal AMPbinding domain. Like R531Q, this mutation reduces the binding of AMP and ATP to the isolated nucleotide-binding domains, and prevents activation of the heterotrimer by metabolic stress in intact cells. The mutation was not found in DNA from the patient's father, the only available parent, and is likely to have arisen de novo. Our studies confirm that mutations in PRKAG2 can cause fatal infantile cardiomyopathy, often associated with apparent PHK deficiency. T he most common cause of cardiac glycogenosis in infancy is Pompe disease (glycogen storage disease type II, GSD II), due to deficiency of the lysosomal enzyme acid ␣-1,4-glucosidase (1). The only other glycogenosis causing massive and rapidly fatal cardiomegaly in infants is a variant of phosphorylase b kinase (PHK) deficiency, which has been reported only in a handful of patients (2-7). In these cases, and contrary to what happens in GSD II, glycogen does not accumulate within lysosomes but is free in the cytoplasm of cardiomyocytes, and the disease seems to be restricted to the heart. The molecular basis of this disorder has been a puzzle until recently because none of the several isozymes of PHK is heart-specific or predominantly expressed in the heart (8). The riddle was solved when, in three unrelated sporadic patients, Burwinkel et al. (9) found an identical heterozygous pathogenic mutation (R531Q) in the gene encoding the ␥2-subunit of AMP-activated protein kinase (PRKAG2). This finding prompted us to revisit an infant with fatal infantile cardiac glycogenosis and PHK deficiency that we had briefly described in 1998. We found a novel heterozygous mutation in PRKAG2, thus confirming the seemingly paradoxical association between an enzyme defect and a mutation in an unrelated gene.
T he most common cause of cardiac glycogenosis in infancy is Pompe disease (glycogen storage disease type II, GSD II), due to deficiency of the lysosomal enzyme acid ␣-1,4-glucosidase (1) . The only other glycogenosis causing massive and rapidly fatal cardiomegaly in infants is a variant of phosphorylase b kinase (PHK) deficiency, which has been reported only in a handful of patients (2) (3) (4) (5) (6) (7) . In these cases, and contrary to what happens in GSD II, glycogen does not accumulate within lysosomes but is free in the cytoplasm of cardiomyocytes, and the disease seems to be restricted to the heart. The molecular basis of this disorder has been a puzzle until recently because none of the several isozymes of PHK is heart-specific or predominantly expressed in the heart (8) . The riddle was solved when, in three unrelated sporadic patients, Burwinkel et al. (9) found an identical heterozygous pathogenic mutation (R531Q) in the gene encoding the ␥2-subunit of AMP-activated protein kinase (PRKAG2). This finding prompted us to revisit an infant with fatal infantile cardiac glycogenosis and PHK deficiency that we had briefly described in 1998. We found a novel heterozygous mutation in PRKAG2, thus confirming the seemingly paradoxical association between an enzyme defect and a mutation in an unrelated gene.
PATIENTS AND METHODS
Patient. This baby girl was born at term by caesarian section (due to fetal bradycardia) to nonconsanguineous parents without any family history of cardiac disease or fetal loss. A cardiac ultrasound at 10 wk of age showed severe hypertrophy of both septal (1.52 cm) and atrial (1 cm) walls (Fig. 1, A and B). Left ventricular ejection fraction was 81%, and peak instantaneous left ventricular outflow gradient was 75 mm Hg. Electrocardiography (ECG) showed a short PR-interval, right atrial enlargement, biventricular hypertrophy and inferior-lateral ischemia (Fig. 2) . Metabolic studies in cultured skin fibroblasts ruled out Pompe disease and defects of ␤-oxidation. A skeletal muscle biopsy showed increased glycogen not contained within lysosomes, suggesting the diagnosis of cardiac PHK deficiency. The child developed progressive ventricular wall thickening and failure to thrive, despite intensified nutritional support. She was on the waiting list for heart transplantation when she died at 5 mo of age from aspiration pneumonia. With the parent's permission, an autopsy was performed 45 min after death and frozen tissues were obtained for biochemical analyses. Again with parental consent, molecular studies were later performed in tissue from the patient and in blood from her father. This study was approved by the Institutional Review Board of Columbia University Medical Center.
Morphology. Heart and skeletal muscle samples were snap-frozen in liquid nitrogen-cooled isopenthane and cryosections were stained with a standard battery of histologic and histochemical reactions (10) .
Biochemistry. Glycogen concentration and the activities of phosphofructokinase and phosphorylase b kinase were measured in whole heart (glycogen) or in 10,000 g supernatants of 10% cardiac muscle homogenates, as described (3) .
Removal of paraffin from tissue sections. Shavings (10 m-thick) of heart and muscle embedded in paraffin were incubated in 1 mL xylene at 55°C for 15 min. The samples were centrifuged at 12,000 g and the pellet was washed twice with 1 mL of 1/1 xylene/ethanol, twice with 1 mL absolute ethanol, then dried at 55°C for 10 min.
DNA extraction and PCR amplification. Genomic DNA extraction was performed on de-paraffinized tissue pellets according to standard procedures (11) . DNA (0.1 g) was used for the PCR amplification of Exon 11 of the PRKAG2 gene using the following primers:
Forward, 5=-TGT AGC TTG CAC TTG TAT TTG AGA; Reverse, 5=-TGA GGG TAA CAG GAG CCA AT.
Sequence analysis of the PCR fragments. a 417-base pair PCR fragment was separated on 2% agarose gel and purified by Perfectprep ® Gel Cleanup kit (Eppendorf, Hamburg, Germany). Purified DNA fragments were sequenced with the ABI Prism 3130 Genetic Analyzer (Perkin Elmer Corp, Boston, MA).
Effect of the R384t mutation on nucleotide binding. Plasmids encoding a glutathione-S-transferase (GST) fusion with both nucleotide-binding domains of human AMP-activated protein kinase ␥2 subunit (AMPK-␥2) (cysthathionine ␤ synthase [CBS] motifs 1-4) were expressed in bacteria, and purified on glutathione-Sepharose (12) . The R384T mutation was introduced using the QuikChange site-directed mutagenesis system (Stratagene). The purified GST fusion protein was incubated with glutathione-coupled scintillation proximity assay (SPA) yttrium silicate beads (GE Healthcare), preblocked with 5% gelatin from cold-water fish skin (Sigma Chemical Co.). The beads were washed with buffer A (50 mM HEPES, pH 7.4, 200 mM NaCl and 1 mM DTT) and resuspended to 10 mg/mL. Wells in a 96 well plate were set up with varying concentrations of [ 3 H] AMP or ATP and 0.1 mg SPA beads, and made up to a final volume of 100 L with buffer A. After shaking the plate gently for 15 min, the beads were allowed to settle, and scintillations were counted using a Microbeta 1450 (Perkin-Elmer). Values obtained with blanks containing purified GST without the AMPK-␥2 insert were subtracted.
Effect of the R384t mutation on AMPK activity. The R384T mutation was introduced into a pcDNA3-based vector (12) using mutagenesis as above. Co-expression in HEK-293 cells with myc-tagged ␣1 and ␤1, immunoprecipitation of recombinant complexes using anti-myc antibody, and kinase assays in the resuspended immunoprecipitate were as described previously (12) .
RESULTS
Pathologic, biochemical, and molecular findings. The heart showed marked ventricular hypertrophy (Fig. 3A) , and the right atrial wall was extremely thickened, measuring over 1 cm (Fig. 3B ). Staining with periodic acid Schiff (PAS)
showed greatly increased glycogen content in the myocardium (Fig. 3C ) and, to a lesser extent, in skeletal muscle (Fig. 3E) . In both tissues, glycogen was digested normally by diastase ( Fig. 3D and F) . Electron microscopy confirmed the presence of large pools of normal-looking glycogen ␤-particles, which appeared to disrupt or distort the contractile system of the cardiomyocytes (not shown).
Biochemical assays in postmortem myocardium (frozen within 2 h of death) showed an 8-fold increase in glycogen concentration and undetectable PHK activity. To reassure ourselves that the lack of PHK activity was not a postmortem artifact, we measured the activity of phosphofructokinase (PFK), a notoriously labile glycolytic enzyme, which was not much less in the patient's heart than in two hearts (Table 1) .
Given the clinical, histochemical, and biochemical similarities between this patient and those reported by Burwinkel et al. (9), we did not sequence any of the genes encoding subunits of PHK but sequenced instead the PRKAG2 gene, encoding the ␥2 subunit of AMPK. Sequence analysis revealed a single heterozygous G-to-C change at nucleotide position 1151 (Fig. 4A) . This transition predicts the substitution of an arginine by a threonine at codon 384 ( Fig. 4B and C) .
Effect of the R384t Mutation on the Regulation of AMPK. The ␥2 mutation occurs within the second of four cystathionine ␤-synthase (CBS) motifs that form the regulatory AMP/ ATP binding sites of AMPK (13) . To study the effects of the mutation on the regulation of AMPK by these nucleotides, we first expressed both the wild-type sequence and an R384T mutation of the four CBS motifs from ␥2 as glutathione-Stransferase (GST) fusions in bacteria and purified them on glutathione-Sepharose. Binding of AMP and ATP was then assessed using a new scintillation proximity assay. In the presence of the R384T mutation, the concentration of AMP needed to cause half-maximal binding (B 0.5 ) rose from 41 Ϯ 11 M to 700 Ϯ 130 M, a 17-fold increase (Fig. 5A) . The R384T mutation increased the B 0.5 for ATP by an even larger amount (26-fold), from 160 Ϯ 40 M to 4030 Ϯ 730 M (Fig. 5A) .
To investigate the effect of the mutation on the regulation of AMPK activity, we also introduced the mutation in a pcDNA3-based plasmid encoding full-length human ␥2 (long form) and co-expressed it with myc-tagged ␣1 and ␤1 in human embryonic kidney (HEK-293) cells. AMPK activity was determined in recombinant AMPK complexes immunoprecipitated with anti-myc antibodies (which do not precipitate endogenous AMPK). We harvested the cells both by the "rapid lysis" procedure, which preserves the physiologic phosphorylation state of the regulatory site Thr-172, and by the "slow lysis" procedure, which (at least with the wild type enzyme) yields maximal phosphorylation of Thr-172 due to stresses that occur during cell harvesting (12) . After "slow lysis", we measured activity with and without 200 M AMP to see if the mutant could be allosterically activated by the nucleotide. Figure 5C shows that, as expected, slow lysis caused a 10-fold activation (in the presence of AMP) of the wild-type enzyme compared with rapid lysis (p Ͻ 0.001), and the enzyme harvested by slow lysis was also 70% stimulated by 200 M AMP (p Ͻ 0.001). As shown in Fig. 5 , the basal activity of the R384T mutant after rapid lysis was not significantly different from that of the wild-type, and neither slow lysis nor addition of AMP in the assay caused significant increases in activity.
DISCUSSION
Our patient had prenatal onset (fetal bradycardia leading to caesarian section) of a severe and rapidly fatal infantile hypertrophic nonobstructive cardiomyopathy with massive cardiomegaly due to glycogen storage. The most common cause of neonatal cardiac glycogenosis, Pompe disease, was unlikely on clinical grounds (infants with Pompe disease are floppy, have hepatomegaly and often macroglossia) and was excluded PHK deficiency has been associated with five main syndromes distinguished by inheritance and by tissue involvement: (i) a benign X-linked recessive liver disease of infancy or childhood (14) ; (ii) an autosomal recessive liver and muscle disease (15) ; (iii) a pure myopathy affecting both sexes but predominantly men (16); (iv) an autosomal recessive severe liver disease associated with cirrhosis (17) and (v) the fetal infantile cardiopathy described here.
PHK is a multimeric enzyme composed of four different subunits, ␣, ␤, ␥, and ␦. The enzyme composition is (␣␤␥␦)4.
The ␥ subunit is catalytic and is regulated through the degree of phosphorylation of the ␣ and ␤ subunits. Calcium sensitivity is conferred by the ␦ subunit, which is a tightly bound calmodulin. The involvement of different tissues in the various clinical variants of PHK deficiency is explained by the multiplicity of genes encoding the various subunits and their isoforms, with two genes encoding the ␣ subunit, one the ␤ subunit, two the ␥ subunit, and three encoding calmodulin (14) . The benign X-linked hepatopathy is due to mutations in PHKA2, which encodes a nonmuscle ␣ isozyme. The autosomal recessive liver and muscle form of PHK deficiency is due to mutations in the ␤ subunit, which is encoded by a gene on chromosome 16 (15) . At least some patients with myopathy have mutations in the PHKA1 gene, which is on the proximal long arm of the ϫ chromosome and encodes the muscle ␣ isozyme (18, 19) .
The genetic basis of the "cardiopathic" PHK deficiency has always presented a conundrum because there is no heartspecific PHK isozyme. This riddle was solved when Burwinkel et al. (9) definitively excluded mutations in any of the PHK genes and instead identified, in three of five unrelated patients with the disease, a single mutation in the gene (PRAKG2) encoding the ␥2 subunit of the AMP-activated protein kinase (AMPK) (9) . Thus, the blame was shifted from one complex kinase, PHK to another, AMPK.
AMPK is an ␣␤␥ heterotrimer, where ␣ is the catalytic subunit and ␤ and ␥ are regulatory subunits (20 -22) . It is considered a "cellular fuel gauge", which is switched on by increases in the AMP:ATP ratio, an indicator of cellular energy deficit. Once activated, AMPK switches off ATPconsuming anabolic pathways (e.g., glucose, lipid, and protein synthesis) while switching on ATP-generating catabolic pathways (e.g., uptake and oxidation of glucose and fatty acids). Increases in AMP activate the AMPK complex via two mechanisms. Firstly, AMPK is constitutively phosphorylated at a specific threonine residue (Thr-172) within the ␣ subunit by the tumor suppressor protein kinase LKB1 (23, 24) ; this phosphorylation is required for activity (25, 26) , but dephosphorylation of Thr-172 is inhibited by AMP (12, 27) . Secondly, AMP further activates the phosphorylated enzyme via an allosteric mechanism (28) .
The ␥ subunits of AMPK contain four tandem repeats of a sequence named by Bateman a CBS motif (29) after the enzyme cystathionine ␤-synthase, in which two such repeats occur. CBS motifs act in pairs to form domains now called "Bateman domains" that bind adenosine-containing ligands (13) . The four CBS motifs in the ␥ subunits of AMPK form two domains, each of which binds one molecule of the regulatory ligand, AMP or ATP, in a mutually exclusive manner (13) .
Several groups (30 -34) reported pathogenic mutations in PRKAG2 in adult patients with autosomal dominant hypertrophic cardiomyopathy and Wolff-Parkinson-White syndrome (FHC/WPW), which was considered "a novel glycogen storage of the heart" (30) . The heterozygous mutation found by Burwinkel et al. (9) in the three sporadic cases of infantile cardiomyopathy, R531Q, was not found in any adult patients, although a different mutation affecting the same residue (R531G) was identified in a family with FHC/WPW and 
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childhood onset (31) . The R531Q and R531G mutations neutralize the positively charged side chain of an arginine residue that occurs in the C-terminal Bateman domain, and we have previously reported that these mutations reduce the binding of AMP and ATP (9, 14) . Intriguingly, the mutation in our patient (R384T) neutralizes the positively charged side chain of an arginine residue in the N-terminal Bateman domain that exactly aligns with Arg-531 in the C-terminal Bateman domain. R384 is also adjacent to H383, in which mutation to arginine has been reported to cause adult onset WPW/HCM (32) . Modeling of the Bateman domains (based on the crystal structure of a bacterial enzyme containing similar domains) suggests that these positively charged, basic side chains (H383, R384 and R531) are directly involved in the binding of the negatively charged ␣-phosphate groups of AMP or ATP (14) . Consistent with this, the H383R, R531G and R531Q mutations all interfere with the binding of AMP and ATP to the isolated Bateman domains, and prevent activation of recombinant ␣␤␥ complexes by AMP (9, 14) .We now show that the R384T mutation has similar effects.
In previous studies, the R531G and R531Q mutations not only prevented activation by AMP but also caused an increase in the basal activity of the ␣␤␥ complex, because, we proposed, the mutations interfered with the binding of the inhibitory nucleotide, ATP (9) . Although the R384T mutation also caused a marked reduction in ATP binding (Fig. 5B) , we did not observe any increase in the basal activity of the ␣1␤1␥2 complex expressed in HEK293 cells (Fig. 5C) .
The three cases of R531Q mutation reported by Burwinkel et al. (9) were sporadic and in the one case where they were available, both parental DNAs were normal. Our patient was also a sporadic case and her father did not harbor the mutation. Although the mother could not be studied, it is likely that this was also a de novo mutation.
Our findings confirm the causative role of PRKAG2 mutations in the fatal infantile hypertrophic cardiomyopathy hitherto erroneously attributed to PHK deficiency. They also add a new "severe" mutation to that described by Burwinkel and coworkers (9) . However, several questions remain unanswered, as noted by those authors (9).
(1) Our discovery does not completely resolve the question of the "pseudo-PHK deficient cardiopathy" of infancy, because two children in the series of five described by Burwinkel et al. (9) did not harbor mutations in PRKAG2. (2) It is not clear whether AMPK deficiency is confined to the heart or also affects other tissues. By Northern blotting of human tissues, the ␥2 isoform is widely expressed, although most abundant in skeletal and cardiac muscle (35) . The finding of increased glycogen in the skeletal muscle biopsy from our patient and from one of the patients harboring the R531Q mutation (9) suggests a more widespread defect, although the heart is selectively affected. (3) The cause of glycogen accumulation remains unclear, although Burwinkel et al. suggested that (despite the loss of AMP activation caused by the mutation) the basal phosphorylation and activity of AMPK are increased by the R531Q mutation (9) . This may result in increased glucose uptake into cardiomyocytes, increased levels of glucose-6-phosphate (G6P), and activation of glycogen synthase. This scenario would also explain the presence of abnormal glycogen (polyglucosan) observed in the heart of adult patients (30) , which could be due to a skewed ratio between glycogen synthase and glycogen branching enzyme, as seen in branching enzyme deficiency and also in PFK deficiency (36) . (4) The reasons for the apparent lack of PHK activity in tissue extracts from these patients remains unclear. AMPK was reported to phosphorylate PHK in cell-free assays (37) , although the significance of this finding has been questioned (38) . One trivial reason for the lack of PHK activity may be the extreme lability of the enzyme, which often has to be measured in postmortem tissues.
Irrespective of the exact pathogenesis, mutations in the ␥2 subunit of AMPK have to be considered an important cause of congenital hypertrophic nonobstructive cardiomyopathy and patients should be screened for PRKAG2 mutations. Given the predominant, if not exclusive, involvement of the heart, cardiac transplantation is an option to be considered in this otherwise rapidly fatal condition.
